ImpriMed: Funding, Investors & Team (Oct 2026)
ImpriMed offers advanced personalized medicine that is conveniently available for pets suffering from blood cancer conditions. The company's main offering, the Personalized Prediction Profile, has been utilized by qualified veterinary oncologists, benefiting more than 4,000 dogs diagnosed with lymphoma and leukemia. With ImpriMed's assistance, veterinarians can promptly and confidently make treatment choices. This groundbreaking cancer care approach has been documented in a scientific journal and showcased at prominent conferences, garnering support from over 200 veterinary oncologists at over 80 specialty hospitals across the United States.
ImpriMed has raised $23.0M across 3 funding rounds on record, the most recent a Series A of $23.0M announced in Dec 2023.
That round is above the $8.4M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
ImpriMed Company Profile and Key Stats
Latest funding round on record: Dec 2023.
ImpriMed Funding Rounds
2 of 3 rounds were announced without a disclosed amount and are excluded from the total.
ImpriMed announced a Seed in Aug 2022; the amount was not disclosed.
1.3 years later, an undisclosed round was announced in Nov 2023 with no disclosed amount.
1 month later, a Series A of $23.0M was announced in Dec 2023.
ImpriMed Founders and Leadership Team
Contact details for the ImpriMed team: 1 of 1 has an email address on file.
Start 14-day free trial →ImpriMed Funding Compared to Other Biotechnology Startups
ImpriMed's latest round of $23.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like ImpriMed in Biotechnology and Palo Alto
Companies Similar to ImpriMed
Prolific Machines is a biotech company located in San Francisco, California, that was established in 2020. It…
Altay Therapeutics is a biotech company focused on finding and discovering small molecule therapies for…
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
ImpriMed Funding FAQs
What does ImpriMed do?
ImpriMed offers advanced personalized medicine that is conveniently available for pets suffering from blood cancer conditions. The company's main offering, the Personalized Prediction Profile, has been utilized by qualified veterinary oncologists, benefiting more than 4,000 dogs diagnosed with lymphoma and leukemia. With ImpriMed's assistance, veterinarians can promptly and confidently make treatment choices. This groundbreaking cancer care approach has been documented in a scientific journal and showcased at prominent conferences, garnering support from over 200 veterinary oncologists at over 80 specialty hospitals across the United States.
How much funding has ImpriMed raised?
ImpriMed has raised $23.0M across 3 rounds on record. The most recent is a Series A of $23.0M announced in Dec 2023.
When did ImpriMed last raise funding?
ImpriMed's most recent funding round on record is a Series A of $23.0M, announced in Dec 2023.
Who is the CEO of ImpriMed?
Sungwon Lim is listed as CEO at ImpriMed.
Where is ImpriMed headquartered?
ImpriMed is based in Palo Alto, California, United States.
How many employees does ImpriMed have?
ImpriMed is in the 11-50 employee band.
How does ImpriMed's funding compare to other Biotechnology startups?
ImpriMed's latest round of $23.0M is above the $8.4M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's ImpriMed Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for ImpriMed is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.